Compare RERE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RERE | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | China | Germany |
| Employees | 2389 | 4553 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 934.1M |
| IPO Year | 2021 | N/A |
| Metric | RERE | EVO |
|---|---|---|
| Price | $5.12 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 792.2K | 91.4K |
| Earning Date | 05-19-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | $1.37 |
| Revenue Next Year | $22.93 | $10.05 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $2.31 |
| 52 Week High | $6.47 | $4.80 |
| Indicator | RERE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 46.32 |
| Support Level | $4.18 | $2.63 |
| Resistance Level | $5.20 | $3.78 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 94.97 | 33.38 |
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.